Product Description
Mechanisms of Action: HCV-NS5B Inhibitor, NN Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatitis A|Hepatitis C|Insomnia
Phase 1: Hepatitis A|Hepatitis C|Healthy Volunteers|Hepatitis C, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| A8121023 | P1 |
Completed |
Hepatitis C, Chronic |
2011-05-01 |
2019-03-19 |
Treatments |
|
| A8121008 | P1 |
Completed |
Hepatitis C |
2011-02-01 |
2019-03-18 |
Treatments |
|
| A8121018 | P1 |
Terminated |
Healthy Volunteers |
2009-04-01 |
2019-03-18 |
Treatments |
|
| A8121013 | P1 |
Completed |
Healthy Volunteers |
2009-02-01 |
2019-03-18 |
Treatments |
|
| A8121006 | P1 |
Completed |
Hepatitis C, Chronic|Hepatitis A |
2008-12-01 |
2019-03-18 |
Treatments |
|
| A8121004 | P1 |
Completed |
Hepatitis C |
2008-09-01 |
2019-03-18 |
Treatments |
|
| A8121002 | P1 |
Completed |
Hepatitis C|Hepatitis A |
2008-06-01 |
2019-03-21 |
Treatments |
|
| 2009-009214-40 | P2 |
Completed |
Unknown |
2012-01-27 |
2022-03-13 |
Treatments |
|
| FITNESS | P2 |
Completed |
Hepatitis A|Hepatitis C |
2012-01-01 |
2019-03-19 |
Treatments |
|
| A8121007 | P2 |
Completed |
Hepatitis A|Hepatitis C |
2010-03-01 |
2019-03-18 |
Treatments |
|
| 2006-7041-83/hah | P2 |
Not yet recruiting |
Insomnia |
None |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/27/2023 |
PubMed |
Inhibition of HEV Replication by FDA-Approved RdRp Inhibitors. |
|
01/01/2021 |
PubMed |
SARS-CoV-2 and SARS-CoV: Virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12). |